Cough News and Research

RSS

Report highlights successes in improving maternal health, reducing child mortality

Rapid expansion of programs to prevent HIV transmission to babies and vaccinate children show how results can be achieved in relatively little time.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease.

23 May 2013

Researchers find that over 40% of patients treated for COPD did not actually have the disease

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive pulmonary disease.

23 May 2013

Genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for lung disease

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.

22 May 2013

U-M-led researchers examine factors that contribute to resurgence of pertussis

Whooping cough has exploded in the United States and some other developed countries in recent decades, and many experts suspect ineffective childhood vaccines for the alarming resurgence.

21 May 2013

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

A small, easily implantable device called the Lung Volume Reduction Coil may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial effects of the device persist more than a year after initial treatment.

21 May 2013

People exposed to wood and tobacco smoke are at greater risk for developing COPD

People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according to the results of a new population-based study conducted by researchers in Colombia.

21 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Tips to keep dog park visits safe, healthy for dogs and dog owners

Dog parks are a great place to socialize dogs and let them play, but they also have some hidden dangers, according to a Kansas State University veterinarian.

20 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Scientists make novel discoveries concerning current vaccine against whooping cough

Scientists at Trinity College Dublin have made novel discoveries concerning the current vaccine against whooping cough that may lead to the development of an improved future vaccine.

13 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

COPD patients with allergic phenotype have increased risk of lower respiratory symptoms, exacerbations

Patients with chronic obstructive pulmonary disease (COPD) who also have allergic disease have higher levels of respiratory symptoms and are at higher risk for COPD exacerbations, according to a new study from researchers at Johns Hopkins University in Baltimore.

10 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Perrigo net sales increase 18% to $920M in third quarter 2013

Perrigo Company today announced results for its third quarter ended March 30, 2013.Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share.

7 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

Somalia launches pentavalent vaccine with support from GAVI, UNICEF, WHO

"Coinciding with World Immunization Week, the Somali government announced on 24 April its intention to vaccinate all children under the age of one with a new five-in-one vaccine, known as a pentavalent vaccine, funded by the GAVI Alliance, with [UNICEF] and the [WHO] as implementing partners," IRIN reports.

30 Apr 2013

Cough News and Research

Report highlights successes in improving maternal health, reducing child mortality

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

CREON Delayed-Release Capsules now available in US for patients with EPI

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

Researchers find that over 40% of patients treated for COPD did not actually have the disease

Genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for lung disease

U-M-led researchers examine factors that contribute to resurgence of pertussis

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

People exposed to wood and tobacco smoke are at greater risk for developing COPD

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Tips to keep dog park visits safe, healthy for dogs and dog owners

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Scientists make novel discoveries concerning current vaccine against whooping cough

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

COPD patients with allergic phenotype have increased risk of lower respiratory symptoms, exacerbations

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Perrigo net sales increase 18% to $920M in third quarter 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Somalia launches pentavalent vaccine with support from GAVI, UNICEF, WHO

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News